BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32125410)

  • 1. The Probiotic Conundrum: Regulatory Confusion, Conflicting Studies, and Safety Concerns.
    Freedman SB; Schnadower D; Tarr PI
    JAMA; 2020 Mar; 323(9):823-824. PubMed ID: 32125410
    [No Abstract]   [Full Text] [Related]  

  • 2. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
    Hibberd PL; Davidson L
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S137-40; discussion S144-51. PubMed ID: 18181720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.
    Mattia A; Merker R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S115-8; discussion S144-51. PubMed ID: 18181714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs.
    Hoffman FA; Heimbach JT; Sanders ME; Hibberd PL
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S53-7. PubMed ID: 18181723
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical research on probiotics: the interface between science and regulation.
    Tamayo C
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S101-3; discussion S144-51. PubMed ID: 18181711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and efficacious probiotics: what are they?
    Reid G
    Trends Microbiol; 2006 Aug; 14(8):348-52. PubMed ID: 16809039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticipating new consumer protection challenges in the food and drug marketplace.
    Parnes LB
    Food Drug Law J; 2008; 63(2):593-9. PubMed ID: 18561480
    [No Abstract]   [Full Text] [Related]  

  • 9. Science and regulation. Probiotics: finding the right regulatory balance.
    Hoffmann DE; Fraser CM; Palumbo FB; Ravel J; Rothenberg K; Rowthorn V; Schwartz J
    Science; 2013 Oct; 342(6156):314-5. PubMed ID: 24136953
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulating the safety of probiotics--the European approach.
    von Wright A
    Curr Pharm Des; 2005; 11(1):17-23. PubMed ID: 15638749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics in the United States.
    Vanderhoof JA; Young R
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S67-72; discussion S144-51. PubMed ID: 18181726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health claims substantiation for probiotic and prebiotic products.
    Sanders ME; Heimbach JT; Pot B; Tancredi DJ; Lenoir-Wijnkoop I; Lähteenmäki-Uutela A; Gueimonde M; Bañares S
    Gut Microbes; 2011; 2(3):127-33. PubMed ID: 21646865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injecting Safety into Supplements - Modernizing the Dietary Supplement Law.
    Cohen PA; Bass S
    N Engl J Med; 2019 Dec; 381(25):2387-2389. PubMed ID: 31851798
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of probiotics as biologic drugs.
    Hoffman FA
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S125-7; discussion S144-51. PubMed ID: 18181717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergen-free probiotics.
    Mogna G; Strozzi GP; Mogna L
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S201-4. PubMed ID: 18685500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American roulette--contaminated dietary supplements.
    Cohen PA
    N Engl J Med; 2009 Oct; 361(16):1523-5. PubMed ID: 19812394
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of probiotics.
    Donohue DC
    Asia Pac J Clin Nutr; 2006; 15(4):563-9. PubMed ID: 17077077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contaminated dietary supplements.
    Carvajal R
    N Engl J Med; 2010 Jan; 362(3):274; author reply 274. PubMed ID: 20089984
    [No Abstract]   [Full Text] [Related]  

  • 19. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 20. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.